| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dendritic Cells | 15 | 2020 | 1085 | 2.460 |
Why?
|
| Immunologic Memory | 3 | 2021 | 374 | 1.400 |
Why?
|
| Th1 Cells | 8 | 2020 | 250 | 1.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2021 | 1586 | 1.240 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 697 | 1.210 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2021 | 1016 | 1.050 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2020 | 182 | 1.020 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 657 | 0.990 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2020 | 235 | 0.990 |
Why?
|
| Adaptive Immunity | 2 | 2015 | 149 | 0.960 |
Why?
|
| Fetal Blood | 9 | 2013 | 482 | 0.890 |
Why?
|
| Dog Diseases | 2 | 2020 | 73 | 0.830 |
Why?
|
| Immunity, Innate | 2 | 2015 | 677 | 0.760 |
Why?
|
| Receptors, IgG | 1 | 2021 | 102 | 0.750 |
Why?
|
| CD40 Antigens | 2 | 2012 | 104 | 0.720 |
Why?
|
| Immune System | 1 | 2020 | 279 | 0.670 |
Why?
|
| Vaccination | 5 | 2019 | 1123 | 0.660 |
Why?
|
| Immunotherapy | 7 | 2019 | 3341 | 0.650 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 419 | 0.650 |
Why?
|
| T-Lymphocytes | 8 | 2020 | 3869 | 0.640 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 45 | 0.600 |
Why?
|
| Bystander Effect | 1 | 2016 | 23 | 0.570 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 234 | 0.550 |
Why?
|
| B7 Antigens | 1 | 2016 | 84 | 0.540 |
Why?
|
| Cytokines | 3 | 2015 | 2809 | 0.530 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 284 | 0.530 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 51 | 0.520 |
Why?
|
| Cytosol | 1 | 2015 | 238 | 0.510 |
Why?
|
| Peptides | 3 | 2020 | 1479 | 0.500 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 406 | 0.490 |
Why?
|
| Porins | 5 | 2000 | 55 | 0.490 |
Why?
|
| Vaccines | 1 | 2017 | 389 | 0.420 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2011 | 20 | 0.410 |
Why?
|
| Animals | 32 | 2022 | 59536 | 0.410 |
Why?
|
| Doxorubicin | 1 | 2019 | 3005 | 0.400 |
Why?
|
| Interferon-gamma | 8 | 2017 | 1144 | 0.400 |
Why?
|
| Stress, Physiological | 1 | 2015 | 492 | 0.400 |
Why?
|
| Mice, Inbred BALB C | 6 | 2020 | 2314 | 0.390 |
Why?
|
| AIDS Vaccines | 1 | 2011 | 78 | 0.390 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 984 | 0.350 |
Why?
|
| Th2 Cells | 2 | 2007 | 257 | 0.340 |
Why?
|
| Influenza Vaccines | 3 | 2012 | 635 | 0.340 |
Why?
|
| Neoplasms | 9 | 2020 | 15193 | 0.320 |
Why?
|
| Anthrax Vaccines | 1 | 2007 | 26 | 0.310 |
Why?
|
| Anthrax | 1 | 2007 | 36 | 0.310 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 657 | 0.310 |
Why?
|
| Exotoxins | 1 | 2007 | 77 | 0.310 |
Why?
|
| Bacillus anthracis | 1 | 2007 | 44 | 0.310 |
Why?
|
| Communicable Diseases | 1 | 2009 | 193 | 0.290 |
Why?
|
| Influenza, Human | 2 | 2012 | 925 | 0.280 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 228 | 0.280 |
Why?
|
| Cell Polarity | 1 | 2007 | 208 | 0.280 |
Why?
|
| Antigens, Neoplasm | 3 | 2012 | 1506 | 0.280 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 904 | 0.280 |
Why?
|
| Amino Acyl-tRNA Synthetases | 2 | 2020 | 17 | 0.270 |
Why?
|
| Mice | 22 | 2022 | 34495 | 0.270 |
Why?
|
| Plasmids | 1 | 2007 | 837 | 0.270 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 698 | 0.270 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 354 | 0.270 |
Why?
|
| Ion Channels | 4 | 1999 | 212 | 0.250 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 105 | 0.250 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3230 | 0.230 |
Why?
|
| Cells, Cultured | 8 | 2019 | 5637 | 0.230 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 3 | 2013 | 47 | 0.230 |
Why?
|
| Antigens, CD34 | 6 | 2012 | 593 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 1538 | 0.220 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 61 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 7789 | 0.210 |
Why?
|
| Antibodies | 1 | 2005 | 838 | 0.210 |
Why?
|
| Vaccines, Synthetic | 2 | 2017 | 355 | 0.210 |
Why?
|
| Antigens, CD | 6 | 2009 | 1385 | 0.200 |
Why?
|
| RNA, Messenger | 3 | 2008 | 6150 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2011 | 4078 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 709 | 0.190 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2013 | 73 | 0.190 |
Why?
|
| Dogs | 2 | 2020 | 1155 | 0.190 |
Why?
|
| Alternative Splicing | 3 | 2000 | 584 | 0.190 |
Why?
|
| Lymphocyte Activation | 5 | 2009 | 1688 | 0.190 |
Why?
|
| Mitochondria, Muscle | 1 | 2000 | 50 | 0.180 |
Why?
|
| Sezary Syndrome | 2 | 2014 | 159 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 249 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 2390 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 42 | 0.180 |
Why?
|
| History, 19th Century | 2 | 2011 | 154 | 0.180 |
Why?
|
| Arthralgia | 1 | 2020 | 89 | 0.180 |
Why?
|
| Osteoarthritis | 1 | 2020 | 94 | 0.180 |
Why?
|
| Exons | 2 | 2000 | 1328 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 6942 | 0.170 |
Why?
|
| Bone Marrow Purging | 2 | 2011 | 86 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7222 | 0.170 |
Why?
|
| Humans | 37 | 2021 | 261506 | 0.170 |
Why?
|
| Carcinogenesis | 2 | 2015 | 1026 | 0.160 |
Why?
|
| Intracellular Space | 2 | 2016 | 77 | 0.160 |
Why?
|
| Adenoviridae | 2 | 2017 | 1459 | 0.160 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 475 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2011 | 574 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 582 | 0.160 |
Why?
|
| Cell Proliferation | 5 | 2015 | 7226 | 0.150 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 66 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 402 | 0.150 |
Why?
|
| Immunophenotyping | 3 | 2019 | 1681 | 0.150 |
Why?
|
| Interleukin-12 | 2 | 2009 | 253 | 0.150 |
Why?
|
| Amino Acid Sequence | 4 | 2020 | 4233 | 0.150 |
Why?
|
| CD3 Complex | 4 | 2013 | 314 | 0.140 |
Why?
|
| CD40 Ligand | 2 | 2007 | 115 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 327 | 0.140 |
Why?
|
| Immunological Synapses | 2 | 2012 | 28 | 0.140 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 17 | 0.140 |
Why?
|
| Antigen Presentation | 3 | 2015 | 272 | 0.130 |
Why?
|
| Macrophages | 2 | 2015 | 1304 | 0.130 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 671 | 0.130 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 26 | 0.130 |
Why?
|
| Membrane Glycoproteins | 3 | 2012 | 1073 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 1033 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2015 | 27 | 0.130 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2015 | 7 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 345 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 73 | 0.120 |
Why?
|
| Voltage-Dependent Anion Channels | 5 | 2000 | 35 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2015 | 1146 | 0.120 |
Why?
|
| Dinoprostone | 2 | 2022 | 208 | 0.120 |
Why?
|
| Cell Separation | 4 | 2011 | 612 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 1242 | 0.120 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 318 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 278 | 0.120 |
Why?
|
| Monocytes | 2 | 2016 | 788 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 673 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.110 |
Why?
|
| Influenza in Birds | 1 | 2012 | 26 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 288 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 4053 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 86 | 0.110 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2012 | 20 | 0.110 |
Why?
|
| Vaccines, Inactivated | 1 | 2012 | 175 | 0.110 |
Why?
|
| Fucose | 1 | 2012 | 50 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2017 | 1694 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2013 | 675 | 0.100 |
Why?
|
| Influenza A virus | 1 | 2013 | 270 | 0.100 |
Why?
|
| History, 18th Century | 1 | 2011 | 89 | 0.100 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 320 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2020 | 11965 | 0.100 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 2138 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2012 | 240 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2012 | 3033 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 6915 | 0.090 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 94 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2012 | 2292 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2216 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 1823 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2012 | 546 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 1547 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 3578 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 204 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 216 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2011 | 441 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 6089 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 362 | 0.090 |
Why?
|
| Mitochondria | 4 | 1999 | 1282 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 430 | 0.080 |
Why?
|
| Protein Isoforms | 3 | 2000 | 842 | 0.080 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2009 | 362 | 0.080 |
Why?
|
| Glycerol Kinase | 2 | 1999 | 20 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 864 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2010 | 471 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 495 | 0.080 |
Why?
|
| Langerhans Cells | 1 | 2008 | 50 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2009 | 266 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 1154 | 0.080 |
Why?
|
| Cell Movement | 1 | 2015 | 2466 | 0.080 |
Why?
|
| K562 Cells | 3 | 2014 | 338 | 0.070 |
Why?
|
| X Chromosome | 2 | 1999 | 339 | 0.070 |
Why?
|
| Mice, SCID | 4 | 2013 | 1869 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8865 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 274 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 685 | 0.070 |
Why?
|
| Homeostasis | 1 | 2012 | 950 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 300 | 0.070 |
Why?
|
| Species Specificity | 1 | 2007 | 777 | 0.070 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 943 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2008 | 1038 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 9180 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 137 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2011 | 1914 | 0.070 |
Why?
|
| Female | 8 | 2019 | 141928 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 182 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 2522 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2330 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2013 | 905 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 1999 | 834 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 4654 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2008 | 478 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 212 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 1313 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 174 | 0.060 |
Why?
|
| Transfection | 2 | 2008 | 2944 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 966 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 202 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5319 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2010 | 806 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2173 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 534 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1374 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 1029 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 941 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 1763 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 1399 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 354 | 0.040 |
Why?
|
| Lod Score | 1 | 1999 | 157 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2000 | 73 | 0.040 |
Why?
|
| Retroelements | 1 | 1999 | 47 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 334 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 65 | 0.040 |
Why?
|
| Male | 7 | 2021 | 123000 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1999 | 135 | 0.040 |
Why?
|
| Base Sequence | 3 | 2000 | 4917 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1360 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 598 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 32848 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2000 | 469 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2013 | 626 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2013 | 842 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 11538 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 1471 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 317 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1999 | 259 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2017 | 1048 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 844 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2013 | 5710 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1999 | 512 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2012 | 668 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2005 | 1664 | 0.040 |
Why?
|
| Biomarkers | 1 | 2009 | 5047 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3821 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2017 | 114 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5159 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1999 | 974 | 0.040 |
Why?
|
| Pericytes | 1 | 2017 | 96 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 607 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 328 | 0.030 |
Why?
|
| Cell Survival | 3 | 2011 | 3045 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 3719 | 0.030 |
Why?
|
| Phytochemicals | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7551 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 2927 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 4367 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2014 | 34 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 446 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 2588 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 2527 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 15 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 22 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 83 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 14289 | 0.030 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2012 | 17 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 33 | 0.030 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 1 | 2012 | 14 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2015 | 251 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 403 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 72 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2012 | 159 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2021 | 2295 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 1270 | 0.030 |
Why?
|
| Birds | 1 | 2012 | 92 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2012 | 68 | 0.030 |
Why?
|
| Axin Protein | 1 | 2012 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 2483 | 0.030 |
Why?
|
| Casein Kinase I | 1 | 2012 | 23 | 0.030 |
Why?
|
| Dishevelled Proteins | 1 | 2012 | 59 | 0.030 |
Why?
|
| United States | 1 | 2009 | 15433 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 992 | 0.030 |
Why?
|
| Lymphography | 1 | 2011 | 51 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 29902 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 2693 | 0.030 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 80 | 0.030 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 42 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 663 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 852 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 107 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 2010 | 14 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 193 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2010 | 31 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 113 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2010 | 72 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 52 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 143 | 0.020 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 2 | 1999 | 17 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 778 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2012 | 221 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 931 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2009 | 18 | 0.020 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 2 | 1999 | 26 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2009 | 39 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 676 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 734 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 543 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2009 | 86 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 798 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2009 | 77 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 148 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 319 | 0.020 |
Why?
|
| Cell Line | 2 | 2011 | 5114 | 0.020 |
Why?
|
| Adult | 2 | 2012 | 77950 | 0.020 |
Why?
|
| Receptor, EphA4 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 91 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1998 | 2819 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 688 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 105 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2008 | 127 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 608 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1541 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 14551 | 0.020 |
Why?
|
| Brain | 1 | 2000 | 4113 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1999 | 869 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 560 | 0.020 |
Why?
|
| Prostate | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 1152 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 1618 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2006 | 110 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 1320 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 1528 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 410 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.020 |
Why?
|
| Aged | 3 | 2021 | 70117 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1182 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 114 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 170 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2006 | 170 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 1439 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 835 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3438 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2006 | 202 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2006 | 260 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 731 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 1818 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 86204 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 461 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.010 |
Why?
|
| Blotting, Western | 2 | 1999 | 3536 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 1085 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 747 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5178 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 1665 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Gene Expression | 2 | 1999 | 3570 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2011 | 2967 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 2422 | 0.010 |
Why?
|
| Benzamides | 1 | 2006 | 1832 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 3254 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 1999 | 57 | 0.010 |
Why?
|
| Lipid Bilayers | 1 | 1999 | 52 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 1999 | 45 | 0.010 |
Why?
|
| Yeasts | 1 | 1999 | 74 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1999 | 108 | 0.010 |
Why?
|
| NAD | 1 | 1999 | 89 | 0.010 |
Why?
|
| Permeability | 1 | 1999 | 167 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 21713 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 3001 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 333 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 141 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 355 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5395 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1999 | 292 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7548 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 401 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 218 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 6295 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 717 | 0.010 |
Why?
|
| Introns | 1 | 1998 | 432 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 12926 | 0.010 |
Why?
|
| Liposomes | 1 | 1999 | 684 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 1635 | 0.010 |
Why?
|
| Piperazines | 1 | 2006 | 2101 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 1062 | 0.010 |
Why?
|
| COS Cells | 1 | 1996 | 377 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8223 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 717 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 7702 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 997 | 0.010 |
Why?
|
| RNA | 1 | 1999 | 1013 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 3518 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 15862 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 6550 | 0.000 |
Why?
|